NASA awards $5 million to artificial retina development efforts

Article

key opens lock in eye

LambdaVision and its partner SpaceTango have been selected by National Aeronautics and Space Administration (NASA) to receive a $5 million reward toward the development of the first protein-based artificial retina. Researchers hope the novel treatment will help blind patients and those with significant sight loss due to advanced retinitis pigmentosa (RP) regain sight. The artificial retina offers secondary application as well in age-related macular degeneration (AMD) andother retinal degenerative diseases, according to the company.

The protein-based, artificial retinas produced in the program imitate human photoreceptors’ light-absorbing properties. They are capable of awakening deteriorating retinas of blind and nearly blind patients, thereby regaining sight.

Related: Companies offer CE, other resources amid coronavirus pandemic

The award includes a series of flights to the International Space Station (ISS) U.S. national laboratory over a three-year period to improve on-orbit processes relating to the production of artificial retinas. LambdaVision and SpaceTango are focused on using the microgravity environment to optimize manufacturing parameters for the assembly of retinal implants.

Artificial retinas are already produced on Earth through a layer-by-layer construction process, but researchers at LambdaVision believes microgravity may reduce the amount of materials required, thereby lowering costs and accelerating manufacturing.

Once the process is legitimized and production goals are reached, it could lead the way for more space-manufactured medical products to be developed.

In a statement, Twyman Clements, co-founder and chief executive officer of SpaceTango says, “As we explore the seemingly immense ways in which microgravity can benefit the development and production of a wide range of products, our long-term collaboration with LambdaVision continues to provide us with valuable learnings that might one day help some patients regain sight and may also lead to other important production discoveries.”

More by Brooke Beery: COVID-19: Key metrics ranked by state

Recent Videos
John Berdahl, MD, overviews the new FYXS Ocular Pressure Adjusting Pump and HERCULES trial at the Glaucoma 360 meeting.
Although 2025 is predicted to remain stable, the forecast for the optical industry still remains uncertain.
Ashley Wallace Tucker, OD, FAAO, FSLS, Dipl ABO, weighs in on what's on the horizon for pediatric myopia management, and provides some tips for diving into scleral lens fitting.
Prominent legislation includes the Corporate Transparency Act and last year's spending bill provision that was struck down.
Shan Lin, MD, outlines a new generation of minimally invasive glaucoma surgeries (MIGS) at Glaucoma 360.
Steven T. Reed, OD, talks Optometry's Meeting and public-facing initiatives that optometrists can take advantage of.
For Ashley Wallace Tucker, OD, FAAO, FSLS, Dipl ABO, last week's conference gives a unique opportunity for optometrists and ophthalmologists to collaborate.
Steven T. Reed, OD, American Optometric Association's president, overviews the 2024 highlights and how the organization plans to extend success into 2025.
Ashley Mills, The Vision Council CEO, outlines new additions to the show that are unveiling what is to come in terms of fashion, technology, and patient care.
© 2025 MJH Life Sciences

All rights reserved.